TGFB1 and cancer: Increased expression of TGF-β is associated with a lack of response to PD-L1 blockade and reduced survival in some cancers,23 and inhibition of the TGF-β pathway may help patients with NSCLC to overcome resistance to anti-PD-(L)1 treatment.